Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to close cancer screening gaps for rural families

NCT ID NCT07381985

Disease control Sponsor: University of Vermont Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a two-year follow-up program for 200 adults with hereditary cancer syndromes like BRCA or Lynch syndrome. Participants get personalized care plans and regular check-ins with a genetics doctor to help them follow cancer prevention and screening guidelines. The goal is to see if this support improves how well people stick to recommended care, especially those living in rural areas.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Longitudinal Cancer Genetics Follow-Up Program (behavioral intervention)
What this could lead to
If successful, this program could help more people with hereditary cancer risks get the right screenings and preventive care, potentially catching cancers earlier or preventing them.
What could go wrong
This is a small, early-stage study with only 200 participants, and it focuses on adherence rather than directly preventing cancer. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of all genders must be ≥ 18 years of age. * Patients must have a known pathogenic germline variant in a cancer risk gene that was identified by a CLIA-approved lab more than one year ago. * Patients must be able to accurately provide self-report data (i.e., per clinical judgment, cognitive function is intact). * Patients must be able to complete questionnaires in English. * Patients must have the ability to provide informed consent. Exclusion Criteria: \- Patients who tested positive for a germline pathogenic variant associated with cancer risk \< 1 year ago are not eligible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 hereditary breast and ovarian cancer syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast-ovarian cancer, familial, susceptibility to, 1 Colorectal Neoplasms, Hereditary Nonpolyposis hereditary neoplastic syndrome Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 hereditary breast and ovarian cancer syndrome Hereditary cancer syndromes Lynch syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Vermont Medical Center

    Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.